Showing 1561-1570 of 1614 results for "".
- Novartis Exits Antibacterial, Antiviral Researchhttps://modernod.com/news/novartis-exits-antibacterial-antiviral-research/2480028/Novartis will close its antibacterial and antiviral research operations in Emeryville, California as part of CEO Vas Narasimhan’s plans to narrow the drugmaker’s R&D focus. Spokesman Ryan McBride said while “there is a commercial market for these medicines…we do not believe
- Novartis Announces Intention to Spinoff Alcon Into Standalone Companyhttps://modernod.com/news/novartis-announces-intention-to-spinoff-alcon-and-launch-a-5-billion-share-buyback/2480055/After months of speculation, Novartis confirmed on Friday its intention to spinoff Alcon into a separately-traded standalone company. The major transaction would enable Novartis to focus on bringing new drugs to market, while allowing Alcon to focus on its core offerings in the surgical and visio
- Former P&G And Cincinnati Children’s Executive Katherine Overbey Joins OneSight As President And Executive Directorhttps://modernod.com/news/former-pg-and-cincinnati-childrens-executive-katherine-overbey-joins-onesight-as-president-and-executive-director/2480057/Global vision care nonprofit OneSight announced that Katherine “K-T” Overbey will be joining the organization as President and Executive Director. Ms. Overbey brings a distinct blend of blue-chip corporate and nonprofit experience in both developed and emerging markets, as well as a s
- Ultrasonic Phaco Remains Dominant, but New Technologies Ready to Challengehttps://modernod.com/news/ultrasonic-phaco-remains-dominant-but-new-technologies-ready-to-challenge/2480114/Market Scope expects surgeons to perform nearly 18.5 million phaco procedures globally in 2018, and dedicated packs and accessories will make up more than 72 percent of the $1.6 billion in global cataract equipment revenues. Two factors will fuel modest growth in the cataract equipment mar
- Wize Pharma Announces Presentation of New Data on LO2A in the Treatment of Dry Eye Syndrome in Patients with Sjögren’s Syndromehttps://modernod.com/news/wize-pharma-announces-presentation-of-new-data-on-lo2a-in-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogrens-syndrome/2480143/Wize Pharma announced recently reported new data on a formula known as LO2A, a product that Wize has in-licensed certain rights to purchase, market, sell and distribute. The poster presentation presented at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting
- President Trump Outlines Plan to Lower Drug Costshttps://modernod.com/news/president-trump-outlines-plan-to-lower-drug-costs/2480151/President Donald Trump on Friday unveiled plans to increase competition in the prescription medicine market and lower patients’ out-of-pocket costs in an effort to tackle high drug prices in the US. Under the plan, dubbed American Patients First, rules preventing government programmes from
- Siemens Healthineers and Hill-Rom to Provide Comprehensive Diabetes Care for Primary Care Facilitieshttps://modernod.com/news/siemens-healthineers-and-hill-rom-to-provide-comprehensive-diabetes-care-for-primary-care-facilities/2480156/Siemens Healthineers and Hill-Rom signed a co-marketing agreement to provide a suite of point-of-care diagnostic instruments that, for the first time, enable primary healthcare providers in the United States to bridge gaps in diabetes care and satisfy value-based quality measures in a single offi
- ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eyehttps://modernod.com/news/regentree-presents-results-of-a-comparison-study-of-rgn-259-and-approved-prescription-drugs-for-dry-eye-syndrome-in-a-mouse-model-at-arvo/2480176/ReGenTree announced that the company presented results of a comparison study of RGN-259 and marketed products for dry eye syndrome in a dry eye mouse model at the ARVO meeting. The study was conducted by Jaewook Yan
- ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye Syndromehttps://modernod.com/news/regentree-presents-results-of-a-comparison-study-of-rgn-259-and-approved-prescription-drugs-for-dry-eye-syndrome/2480185/ReGenTree, a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals, announced that the company presented results of a comparison study of RGN-259 and marketed products for dry eye syndrome in a dry eye mouse model at ARVO (The Association for Research in Vision and Ophthalmology)
- EyeCare Partners Moves into Cincinnati With Acquisition of Mariemont EyeCarehttps://modernod.com/news/eyecare-partners-moves-into-cincinnati-with-acquisition-of-mariemont-eyecare/2480220/EyeCare Partners LLC (ECP), a network of full-scope medical optometry and ophthalmology practices, has expanded in the Cincinnati optometry market with the acquisition of Mariemont EyeCare, the optometry practice of Ma